Bone Biologics Corp Warrants
BBLGW
5 hedge funds and large institutions have $134K invested in Bone Biologics Corp Warrants in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
46% less capital invested
Capital invested by funds: $246K → $134K (-$112K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$31.4K |
| 2 |
CS
Clear Street
New York
|
+$8.89K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$25.3K |
| 2 |
EAM
Empery Asset Management
New York
|
-$1.07K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $48K | -$1.07K | -80 | -2% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $38K | +$31.4K | +2,352 | +181% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $37K | -$25.3K | -1,900 | -34% |
|
|
CS
4
Clear Street
New York
| $7K | +$8.89K | +667 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $4K | +$2.8K | +210 | +137% |
|
BBLGW Hedge Fund Activity: Q1 2022 in Review
5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q1 2022, worth a combined $134K — down 46% from $246K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BBLGW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $31.4K. The largest seller was Sabby Management, cutting an estimated $25.3K.
- 5 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q1 2022, up from 4 in Q4 2021.
- Funds reported $134K of Bone Biologics Corp Warrants stock for Q1 2022, down 46% quarter-over-quarter.
- 1 fund opened new Bone Biologics Corp Warrants positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest Bone Biologics Corp Warrants buyer in Q1 2022 was Warberg Asset Management, an estimated $31.4K added.
- The largest Bone Biologics Corp Warrants seller in Q1 2022 was Sabby Management, an estimated $25.3K sold.
Based on aggregated 13F filings for Q1 2022.